Navigation Links
Novel paclitaxel formulation encouraging for treating advanced lung cancer
Date:6/15/2010

The June edition of the Journal of Thoracic Oncology features a study aimed at determining the optimal dose of the chemotherapy drug nab-paclitaxel with carboplatin as a first-line therapy in patients with non-small cell lung cancer (NSCLC). Results will provide researchers with a data needed to guide a phase 3 trial.

The most commonly used combination treatment for patients with NSCLC is carboplatin plus solvent-based paclitaxel. However, this current treatment has major safety and efficacy concerns, such as severe toxicities, nerve damage. As lung cancer is the leading cause of lung cancer death worldwide, there is a critical need for safe chemotherapy treatments to curb this disease.

In this multi-center study, researchers sought to determine the optimal dose of a chemotherapy treatment using a novel paclitaxel formulation, nanoparticle albuminbound (nab-), which can be administered safely at higher doses than the solvent-based paclitaxel and has performed well when treating breast cancer patients. One hundred seventy-five previously untreated patients were enrolled in the study and received treatment with nab-paclitaxel either on a weekly or every-three-week basis. Dosing levels were also investigated.

Overall results showed response rate was greater in weekly doses than in every-three-week doses. Median progression-free survival was similar between both schedules and ranged from 4.8 to 6.9 months in the every-three-week cohorts and 5.6 to 6.4 months in the weekly cohorts. Overall survival was also similar in both groups and ranged from 8.3 to 14.6 months in the every-three-week cohort and 11.3 to 15.0 in the weekly cohort. Most favorable of all the cohorts was the group receiving 100 mg/m2 weekly nab-paclitaxel. This group achieved a 48 percent response rate with 6.2 and 11.3 months of progression-free survival and overall survival, respectively.

In addition to improved anti-tumor activity, nab-paclitaxel administered weekly was associated with less serious adverse events than when administered every three weeks, with significant reductions of nerve damage and muscle and joint pain. More specifically, it was found that a 100 mg/m2 weekly nab-paclitaxel produced less serious adverse events than other doses.

  Weekly dose  Every-three-week dose 
Response rate 47% 30%
ORR 36-56% 24-40%
 Progression-free survival  5.6-6.4 months 4.8-6.9 months
Overall survival  12.0-15.0 months  8.3-14.6 months

Researchers concluded that nab-paclitaxel plus carboplatin is an effective therapy for advanced NSCLC and recommend a phase 3, randomized, multi-center study comparison 100 mg/m2 weekly nab-paclitaxel plus carboplatin to solvent-based paclitaxel plus carboplatin.

"Given the high cumulative dose delivered and the excellent safety and efficacy profile of the patients who received 100 mg/m2 weekly nab-paclitaxel plus carboplatin, we believe this to be the optimal dosing and schedule for phase 3 comparison in patients with advanced NSCLC," confirms lead investigator Mark A. Socinski, MD of the University of North Carolina Lineberger Comprehensive Cancer Center.


'/>"/>

Contact: Megan Richter
mrichter@spectrumscience.com
202-587-2556
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. Novel Drug Combats Advanced Melanoma
2. Novel RNA interference screening technique identifies possible path for malignant glioma treatment
3. Novel anti-malarial drug candidate found by UT Southwestern researchers
4. ASCO data highlight novel anti-cancer approach that exposes tumors to immune attack
5. Research identifies patterns of CD24, a novel biomarker for non-small cell lung carcinomas
6. Third European Novel Food Approval Received by Tahitian Noni International
7. Novel nanoparticles prevent radiation damage
8. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
9. Novel Method Eyed for Normalizing Blood Sugar
10. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
11. MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology , a provider ... and attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service and ... biometric face recognition to enable users to check in and out from anywhere ...
(Date:3/28/2017)... ... March 28, 2017 , ... METTLER TOLEDO Process ... in power plant water and steam. , Chlorides and sulfates cause pitting and ... to extensive maintenance and unplanned shutdowns. Monitoring these ions at low ppb levels ...
(Date:3/28/2017)... Florida (PRWEB) , ... March 28, 2017 , ... The ... Corp to raise money to for the Toys for Tots Literacy Campaign at their ... budget in excess of $70 billion, the U.S. ranks at number 14 internationally in ...
(Date:3/28/2017)... ... , ... A minimally invasive porcelain veneer is increasing in ... of Dental Laboratories (NADL) is informing dentists about the benefits of minimally invasive ... laboratories and technicians that create these veneers. , According to National Board ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved ... procedure, and this procedure adds to SkyLex Advanced Surgical’s already comprehensive list ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... VICTORIA and TORONTO , ... Canada,s leading full service medical device development ... Group, the visionary Toronto -based medical ... entity will better serve medtech companies throughout ... increased resources and experienced medical device talent spanning the ...
(Date:3/28/2017)... and TEL AVIV, Israel , March 28, ... in Israel . This new business entity, Emosis ... mostly dedicated to research and development of novel assays complementing the ... also, when relevant, locally support commercialization and sales development of Emosis ... This strategic ...
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
Breaking Medicine Technology: